Voloridge Investment Management LLC Purchases New Shares in Allakos Inc (NASDAQ:ALLK)

Voloridge Investment Management LLC acquired a new stake in shares of Allakos Inc (NASDAQ:ALLK) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 39,654 shares of the company’s stock, valued at approximately $3,118,000.

A number of other institutional investors also recently modified their holdings of the business. Tower Research Capital LLC TRC purchased a new stake in shares of Allakos in the 3rd quarter worth about $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Allakos during the 3rd quarter valued at about $113,000. Bank of Montreal Can bought a new stake in shares of Allakos during the 2nd quarter valued at about $63,000. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Allakos during the 1st quarter valued at about $142,000. Finally, SG Americas Securities LLC increased its position in shares of Allakos by 27.5% during the second quarter. SG Americas Securities LLC now owns 4,819 shares of the company’s stock valued at $209,000 after buying an additional 1,040 shares during the period. 68.68% of the stock is currently owned by institutional investors and hedge funds.

ALLK opened at $95.98 on Tuesday. The stock has a market cap of $4.62 billion, a PE ratio of -43.63 and a beta of -1.13. The business has a 50 day moving average of $77.30 and a 200-day moving average of $63.68. Allakos Inc has a 52 week low of $30.32 and a 52 week high of $98.37.

Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.04). Sell-side analysts predict that Allakos Inc will post -1.88 EPS for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Allakos from a “buy” rating to a “hold” rating in a research note on Friday, August 16th. William Blair reaffirmed a “buy” rating on shares of Allakos in a research report on Friday, August 9th. Finally, ValuEngine cut Allakos from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Read More: Most Volatile Stocks

Want to see what other hedge funds are holding ALLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allakos Inc (NASDAQ:ALLK).

Institutional Ownership by Quarter for Allakos (NASDAQ:ALLK)

Leave a Reply

Your email address will not be published. Required fields are marked *